¼¼°èÀÇ ¼ºÀå È£¸£¸ó °áÇÌÁõ ½ÃÀå º¸°í¼­(2025³â)
Growth Hormone Deficiency Global Market Report 2025
»óǰÄÚµå : 1720806
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,183,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,938,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,692,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼ºÀå È£¸£¸ó °áÇÌÁõ ½ÃÀå ±Ô¸ð´Â ¾ÕÀ¸·Î ¼ö³â°£ °­·ÂÇÑ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. 2029³â¿¡´Â CAGR 5.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 54¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº À¯Àü¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê Áõ°¡, ¿¬±¸°³¹ß ³ë·Â °­È­, Gh Áúȯ ÀÌȯÀ² Áõ°¡, ÀÓ»ó°Ë»ç¼ö È®´ë·Î ÀÎÇÑ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ±â¼úÀÇ Áøº¸, Ä¡·á ¼±ÅÃÀÇ È®´ë, Áø´Ü ±â¼úÀÇ °³¼±, ÃÖ±ÙÀÇ µ¿Çâ, »ý¸í °øÇÐÀÇ Áøº¸ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.

À¯Àü¼º ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ¼ºÀå È£¸£¸ó °áÇÌÁõ ½ÃÀåÀÇ È®´ë¸¦ À̲ø °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯Àü¼º ÁúȯÀº °³ÀÎÀÇ DNAÀÇ ÀÌ»óÀ̳ª µ¹¿¬º¯ÀÌ¿¡ ±âÀÎÇÏ´Â º´¸®ÇÐÀ̸ç, À¯Àü¼º ¶Ç´Â ÀÚ¿¬ ¹ß»ý Áß ¾î´À ÇϳªÀÔ´Ï´Ù. Áø´Ü±â¼úÀÇ Áøº¸, ÀÎÁöµµÀÇ Çâ»ó, ÀÓ»êºÎ ¿¬·ÉÀÇ »ó½Â, µ¹¿¬º¯À̸¦ ÀÏÀ¸Å°´Â ȯ°æ ¿äÀÎ, Àα¸ Áõ°¡, ÀÌȯ ȯÀÚÀÇ »ýÁ¸À²ÀÇ Çâ»ó µî, ¿©·¯ ¿äÀÎÀÌ ¸¸¿¬À²ÀÇ »ó½Â¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¼ºÀå È£¸£¸ó °áÇÌÁõ Ä¡·á´Â ƯÁ¤ À¯Àü Áúȯ°ú °ü·ÃµÈ ¼ºÀå °ü·Ã ÇÕº´ÁõÀ» °ü¸®ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 12¿ù ¿µ±¹ Á¤ºÎºÎ¹®ÀÎ º¸°Ç»çȸÀÇÇкÎ(DHSC)°¡ ¹ßÇ¥ÇÑ º¸°í¼­¿¡ µû¸£¸é 2022³â 10¿ù¿¡´Â ¾à 3¸¸ 3,000°³ÀÇ ÃÑ À¯Àüü »ó´çÇÑ ¼­¿­ÀÌ °áÁ¤µÇ¾î Æò±Õ Áø´Ü ¼öÀ²Àº 32%·Î, ƯÁ¤ Áúȯ¿¡¼­´Â 61%·Î »ó½ÂÇß½À´Ï´Ù. ±× °á°ú, À¯Àü¼º ÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ¼ºÀå È£¸£¸ó °áÇÌÁõ ½ÃÀåÀÇ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

¼ºÀå È£¸£¸ó °áÇÌÁõ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº ¼Ò¾Æ ¼ºÀå È£¸£¸ó °áÇÌÁõ(GHD)¿¡ ´ëÇÑ ºñº¯Çü ¼Ò¸¶Æ®·ÎÇɰú °°Àº Çõ½ÅÀûÀÎ Ä¡·áÀÇ °³Ã´¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. »ç¿ëµÇ´Â ¼ºÀå È£¸£¸ó°ú °°Áö¸¸, ½ºÄ«ÀÌÆ®·ÎÆÄ·Î ÁÖ 1ȸ Åõ¿©ÇÒ ¼ö ÀÖµµ·Ï Á¦Á¦È­µÈ °ÍÀÔ´Ï´Ù. Pharma A/S´Â ¼Ò¾Æ GHDÀÇ ÁÖ 1ȸ Ä¡·á·Î¼­ SKYTROFA(lonapegsomatropin)¸¦ ¹ß¸ÅÇß½À´Ï´Ù. È£¸£¸ó ¿¬ÀÏ Åõ¿© ¿ä¹ý¿¡ ºñÇØ Ä¡·á ¼ºÀûÀÌ Çâ»óµÉ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - °Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°ÀÇ ¿µÇâ°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, Àü·«

Á¦36Àå ºÎ·Ï

SHW
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Growth hormone deficiency (GHD) is a medical condition in which the pituitary gland does not produce enough growth hormone (GH). This deficiency leads to stunted growth and development in children and various metabolic issues in adults. Growth hormone deficiency can be congenital (present at birth) or acquired due to injury, tumors, infections, or other medical conditions affecting the pituitary gland.

The primary types of growth hormone deficiency are pediatric growth hormone deficiency and adult growth hormone deficiency. Pediatric growth hormone deficiency focuses on children with inadequate growth hormone production, resulting in stunted growth and delayed development. Treatments involved are pharmacological therapy, recombinant human growth hormone, human pituitary gland extracts, and surgery. The various routes of administration include intravenous, intramuscular, and others. They are distributed through several channels, such as hospital pharmacy, online pharmacy, and retail pharmacy, and are used by multiple end users, including hospitals, home care, specialty clinics, and others.

The growth hormone deficiency market research report is one of a series of new reports from The Business Research Company that provides growth hormone deficiency market statistics, including the growth hormone deficiency industry global market size, regional shares, competitors with the growth hormone deficiency market share, detailed growth hormone deficiency market segments, market trends, and opportunities, and any further data you may need to thrive in the growth hormone deficiency industry. This growth hormone deficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth hormone deficiency market size has grown strongly in recent years. It will grow from $4.06 billion in 2024 to $4.31 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to the rising number of strategic initiatives, increasing incidences of brain tumors, growing demand for hormone therapies, increased elderly population, and rising government funding for healthcare.

The growth hormone deficiency market size is expected to see strong growth in the next few years. It will grow to $5.42 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth during the forecast period can be attributed to the increasing prevalence of genetic disorders, the rising number of strategic initiatives, enhanced research and development efforts, the growing morbidity of Gh disease, and the expanding number of clinical trials. Key trends in the forecast period include technological advancements, the expansion of treatment options, improvements in diagnostic techniques, recent developments, and progress in biotechnology.

The increasing prevalence of genetic disorders is expected to drive the expansion of the growth hormone deficiency market. Genetic disorders are medical conditions resulting from abnormalities or mutations in an individual's DNA, either inherited or occurring spontaneously. Several factors contribute to their rising prevalence, including advancements in diagnostic technology, increased awareness, rising maternal age, environmental factors causing mutations, population growth, and improved survival rates for affected individuals. Growth hormone deficiency treatments help manage growth-related complications associated with certain genetic conditions. For instance, according to a report published in December 2022 by the Department of Health & Social Care (DHSC), a UK-based government department, approximately 33,000 whole genome equivalents were sequenced in October 2022, with an average diagnostic yield of 32%, rising to 61% in specific conditions. As a result, the increasing prevalence of genetic disorders is fueling the growth of the growth hormone deficiency market.

Leading companies in the growth hormone deficiency market are focusing on developing innovative treatments, such as unmodified somatropin, for pediatric growth hormone deficiency (GHD). Unmodified somatropin is the same growth hormone used in daily GHD treatments but formulated for once-weekly administration with Skytrofa. For example, in September 2023, Ascendis Pharma A/S, a Denmark-based biopharmaceutical company, launched SKYTROFA (lonapegsomatropin) as a once-weekly treatment for pediatric GHD. This innovation enhances convenience, improves adherence, and offers potentially better treatment outcomes compared to traditional daily growth hormone therapies. As the first and only FDA-approved once-weekly treatment for pediatric GHD, it represents a significant advancement in endocrinology and pediatric care.

In February 2022, Pfizer Inc., a US-based pharmaceutical company, partnered with OPKO Health Inc. to advance the treatment of pediatric growth hormone deficiency (GHD). Through this collaboration, Pfizer and OPKO Health aim to develop and commercialize NGENLA (somatrogon), a next-generation long-acting recombinant human growth hormone that reduces the injection frequency from once daily to once weekly. This approach improves treatment adherence, minimizes the burden of disease management, and enhances the overall quality of life for children and adolescents with GHD. OPKO Health Inc. is a US-based company specializing in the development and commercialization of treatments for growth hormone deficiency.

Major players in the growth hormone deficiency market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Eli Lilly and Company, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Genentech Inc., Ipsen Biopharmaceuticals Inc., Opko Health Inc., JCR Pharmaceuticals Co. Ltd., Ferring Pharmaceuticals Inc., Ascendis Pharma A/S, Rani Therapeutics Inc., AnkeBio Co. Ltd., Aeterna Zentaris Inc., Zhongshan Sinobioway Hygene Biomedicine Co. Ltd., Versartis Inc., I-Mab Biopharma Co. Ltd.

North America was the largest region in the growth hormone deficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in growth hormone deficiency report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the growth hormone deficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The growth hormone deficiency market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, and specialized services. The market value includes the value of related goods sold by the service provider or included within the service offering. The growth hormone deficiency market consists of sales of recombinant human growth hormones, long-acting growth hormones and combination therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Growth Hormone Deficiency Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on growth hormone deficiency market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for growth hormone deficiency ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The growth hormone deficiency market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Growth Hormone Deficiency Market Characteristics

3. Growth Hormone Deficiency Market Trends And Strategies

4. Growth Hormone Deficiency Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Growth Hormone Deficiency Growth Analysis And Strategic Analysis Framework

6. Growth Hormone Deficiency Market Segmentation

7. Growth Hormone Deficiency Market Regional And Country Analysis

8. Asia-Pacific Growth Hormone Deficiency Market

9. China Growth Hormone Deficiency Market

10. India Growth Hormone Deficiency Market

11. Japan Growth Hormone Deficiency Market

12. Australia Growth Hormone Deficiency Market

13. Indonesia Growth Hormone Deficiency Market

14. South Korea Growth Hormone Deficiency Market

15. Western Europe Growth Hormone Deficiency Market

16. UK Growth Hormone Deficiency Market

17. Germany Growth Hormone Deficiency Market

18. France Growth Hormone Deficiency Market

19. Italy Growth Hormone Deficiency Market

20. Spain Growth Hormone Deficiency Market

21. Eastern Europe Growth Hormone Deficiency Market

22. Russia Growth Hormone Deficiency Market

23. North America Growth Hormone Deficiency Market

24. USA Growth Hormone Deficiency Market

25. Canada Growth Hormone Deficiency Market

26. South America Growth Hormone Deficiency Market

27. Brazil Growth Hormone Deficiency Market

28. Middle East Growth Hormone Deficiency Market

29. Africa Growth Hormone Deficiency Market

30. Growth Hormone Deficiency Market Competitive Landscape And Company Profiles

31. Growth Hormone Deficiency Market Other Major And Innovative Companies

32. Global Growth Hormone Deficiency Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Growth Hormone Deficiency Market

34. Recent Developments In The Growth Hormone Deficiency Market

35. Growth Hormone Deficiency Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â